214 related articles for article (PubMed ID: 24111533)
1. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
[TBL] [Abstract][Full Text] [Related]
2. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
[TBL] [Abstract][Full Text] [Related]
3. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735
[TBL] [Abstract][Full Text] [Related]
4. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
6. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Ban-Hoefen M; Kelly JL; Bernstein SH; Liesveld J; Constine L; Becker M; Milner L; Phillips G; Friedberg JW
Leuk Lymphoma; 2012 May; 53(5):830-5. PubMed ID: 22023518
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
9. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.
Blaker YN; Eide MB; Liestøl K; Lauritzsen GF; Kolstad A; Fosså A; Smeland EB; Holte H
Leuk Lymphoma; 2014 Oct; 55(10):2319-27. PubMed ID: 24432894
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation.
Kim JW; Kim BS; Bang SM; Kim I; Kim DH; Kim WS; Yang DH; Lee JJ; Lee JH; Kim JS; Sohn SK; Yhim HY; Kwak JY; Yoon SS; Lee JS; Park S; Kim BK;
Ann Hematol; 2011 Dec; 90(12):1409-18. PubMed ID: 21468694
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
Bhatt VR; Vose JM
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
[TBL] [Abstract][Full Text] [Related]
12. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
14. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
16. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma.
Sieniawski M; Staak O; Glossmann JP; Reineke T; Scheuss H; Diehl V; Engert A; Josting A
Ann Hematol; 2007 Feb; 86(2):107-15. PubMed ID: 17103169
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.
Villa D; Crump M; Keating A; Panzarella T; Feng B; Kuruvilla J
Ann Oncol; 2013 Jun; 24(6):1603-9. PubMed ID: 23425946
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
[TBL] [Abstract][Full Text] [Related]
19. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
20. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.
Crocchiolo R; Castagna L; Fürst S; El-Cheikh J; Faucher C; Oudin C; Granata A; Bouabdallah R; Coso D; Chabannon C; Balzarotti M; Santoro A; Blaise D
Bone Marrow Transplant; 2013 Feb; 48(2):249-52. PubMed ID: 22732704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]